Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

41P - Testosterone level and severity of COVID-19 infection in ambispective cohorts: The TESTOVID study

Date

16 Sep 2021

Session

ePoster Display

Presenters

Johanna Noel

Citation

Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684

Authors

J. Noel1, A. Sabouret1, E. Auclin1, J.B. Arlet1, B. Hermann2, J.L. Diehl2, J.S. Hulot3, E. Messas1, G. Detriche4, D. Lebeaux5, S. Baron6, A. Blanchard3, S. Brabant6, B. Djobo7, M. Auvray-Kuentz8, D. Prie9, C. Laouenan10, C. Dorival11, J.C. Barale12, S.M. Oudard13

Author affiliations

  • 1 Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 2 Intensive Care, Hopital European George Pompidou, 75015 - Paris/FR
  • 3 Centre D'investigations Cliniques, Hopital European George Pompidou, 75015 - Paris/FR
  • 4 Vascular Medicine, Hopital European George Pompidou, 75015 - Paris/FR
  • 5 Maladies Infectieuses, Hopital European George Pompidou, 75015 - Paris/FR
  • 6 Biology, Hopital European George Pompidou, 75015 - Paris/FR
  • 7 Physiology, CHU Lille, 59000 - Lille/FR
  • 8 Oncology, APHP Hopital Europeen Georges Pompidou, 75015 - Paris/FR
  • 9 Nephrology, Hopital Necker, 75015 - Paris/FR
  • 10 Epidémiologie, Hopital Bichat, 75018 - Paris/FR
  • 11 Inserm, Hopital Bichat, 75018 - Paris/FR
  • 12 Recherche Clinique, Institut Pasteur, 75015 - Paris/FR
  • 13 Medical Oncology, Hopital European George Pompidou, 75015 - Paris/FR
More

Abstract 41P

Background

Lower risk of COVID-19 was reported in men with prostate cancer receiving androgen deprivation therapy while low levels of testosterone (T) were associated with a more severe disease and poor clinical outcomes in COVID-19 male patients (pts). In the latter case, it is unclear whether low levels of T and dihydrotestoserone (DHT) are risk factors or consequences of COVID-19. Here, we investigated T and DHT levels impact on COVID-19 severity in ambispective cohorts of symptomatic SARS-CoV-2 infected males.

Methods

Both prospective (European Hospital Georges Pompidou patients, P-cohort) and retrospective (French COVID-19 cohort, REacting project, R-cohort) cohorts included male pts admitted for severe COVID-19. The P-cohort included pts admitted in a medical unit (non-ICU) or in ICU immediately (ICU-I). The R-cohort included pts admitted to a medical unit, ICU-I or to ICU secondarily (ICU-S). The size of ICU-S pts group in P-cohort was insufficient to include their data in the analysis. We collected information on pts demographics and COVID-19-related outcomes. T, DHT levels and inflammation markers were measured. Wilcoxon-Mann-Whitney test and chi2-test (or Fisher’s exact test, if appropriate) were performed. All tests were two-sided at 0.05 significance level.

Results

The P-cohort included 71 pts (median age: 64 years) and the R-cohort 89 pts (median age: 62 years). The median duration between admission and measurement of hormone levels was 2 days (range: 0-16) and 0.5 days (range: 0-11) respectively. T and DHT levels were low in all pts as compared to standards and even lower in ICU pts (Table). In the R-cohort, T and DHT lowest values were observed for ICU-I pts and median values for ICU-S pts. Table: 41P

P-cohort R-cohort
Non-ICU n=22 ICU-I n=49 P Non-ICU n=44 ICU-I n=24 ICU-S n=21 p <
Hospital stay (days) 7.23 25.71 0.001 8.26 15.5 18.95 0.001
Death (%) 0 32.65 0.002 2.27 37.5 19.05 0.002
T (nmol/l) 5.55 2.36 0.001 6.28 2.59 5.42 0.011
DHT (nm/l) 0.5 0.25 0.012 0.75 0.34 0.56 0.045

Conclusions

Low T and DHT levels were associated with the severity of the disease and the poorest clinical outcomes in males with severe COVID-19. This suggests that COVID-19 may cause a rapid and profound decrease in androgens levels and that T and DHT serum levels may be used as prognostic markers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Pr. Stéphane Oudard.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.